nnpNeurology, Neuropsychiatry, PsychosomaticsНеврология, нейропсихиатрия, психосоматика2074-27112310-1342"IMA-Press", LLC10.14412/2074-2711-2022-5-4-12nnp-1884Research ArticleLECTURESЛЕКЦИЯEvolution of ideas about the risk of tyramine syndrome developing during therapy with irreversible non-selective monoamine oxidase inhibitors (to the 70th anniversary of the first use of this group of antidepressants)Эволюция представлений о риске развития тираминового синдрома при терапии необратимыми неселективными ингибиторами моноаминоксидазы (к 70-летию начала использования этой группы антидепрессантов)https://orcid.org/0000-0002-9589-3707ДаниловД. С.DanilovD. S.

119021, Москва, ул. Россолимо, 11, стр. 9

11, Rossolimo St., Build. 9, Moscow 119021

clinica2001@inbox.ruhttps://orcid.org/0000-0003-0023-2701БровкоМ. Ю.BrovkoM. Yu.

Клиника ревматологии, нефрологии и профпатологии им. Е.М. Тареева Университетской клинической больницы №3,

119021, Москва, ул. Россолимо, 11, стр. 5

E.M. Tareev Clinic of Rheumatology, Nephrology and Occupational Pathology, University Clinical Hospital №3, 

11, Rossolimo St., Build. 5, Moscow 119021

Клиника психиатрии им. С.С. КорсаковаРоссияS.S. Korsakov Psychiatry ClinicRussian FederationФГАОУ ВО «Первый Московский государственный медицинский университет им. И.М. Сеченова» Минздрава России (Сеченовский Университет)РоссияI.M. Sechenov First Moscow State Medical University (Sechenov University), Ministry of Health of Russia,Russian Federation202220102022145412Copyright © Danilov D.S., Brovko M.Y., 20222022Данилов Д.С., Бровко М.Ю.Danilov D.S., Brovko M.Y.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://nnp.ima-press.net/nnp/article/view/1884

We describe the history of studying of the problem of tyramine syndrome during the treatment with antidepressants, irreversible non-selective monoamine oxidase inhibitors. Data on clinical observations are presented. Early hypotheses of pathogenesis are considered. The period of discovery of the relationship between increased blood pressure and the use of foods containing tyramine is outlined. The transformation of terminology is demonstrated. The events associated with the restriction of the use of therapy are characterized. The formation of the opinion about the exaggeration of the risk of developing tyramine syndrome is analyzed. Data on the involvement in the discussion of the problem of tyramine syndrome of society as a whole are given. 

Описана история изучения проблемы тираминового синдрома при терапии антидепрессантами – необратимыми неселективными ингибиторами моноаминоксидазы. Представлены данные о клинических наблюдениях. Рассмотрены ранние гипотезы патогенеза. Обрисован период открытия взаимосвязи между повышением артериального давления и употреблением пищевых продуктов, содержащих тирамин. Продемонстрирована трансформация терминологии. Охарактеризованы события, связанные с ограничением использования терапии. Проанализировано становление мнения о преувеличении риска развития тираминового синдрома. Приведены данные о вовлеченности в обсуждение проблемы тираминового синдрома общества в целом. 

ингибиторы моноаминоксидазысырная реакциятираминовый синдромгипертонический кризфенелзинтранилципроминизокарбоксазидтираминmonoamine oxidase inhibitorscheese reactiontyramine syndromehypertensive crisisphenelzinetranylcypromineisocarboxazidtyramineReferencesStolberg VB. ADHD medications: history, science, and issues. Santa Barbara: Greenwood; 2017. 275 p.Stolberg VB. ADHD medications: history, science, and issues. Santa Barbara: Greenwood; 2017. 275 p.Phelps J, Carlat D. Four “new” antidepressants. Or are they? Tablet. 2011;12(3):2-9. doi: 10.1037/e625792012-002Phelps J, Carlat D. Four “new” antidepressants. Or are they? Tablet. 2011;12(3):2-9. doi: 10.1037/e625792012-002Wright V, Walker WC, Wood EA. Nialamide as a “Steroid Sparing” agent in the treatment of rheumatoid arthritis. Ann Rheum Dis. 1963;22(5):348-53. doi: 10.1136/ard.22.5.348Wright V, Walker WC, Wood EA. Nialamide as a “Steroid Sparing” agent in the treatment of rheumatoid arthritis. Ann Rheum Dis. 1963;22(5):348-53. doi: 10.1136/ard.22.5.348Smith JA. The use of the isopropyl derivative of isonicotinylhydrazine (marsilid) in the treatment of mental disease: A preliminary report. Am Pract Dig Treat. 1953 Aug;4(8):519-20.Smith JA. The use of the isopropyl derivative of isonicotinylhydrazine (marsilid) in the treatment of mental disease: A preliminary report. Am Pract Dig Treat. 1953 Aug;4(8):519-20.Ogilvie CM. The treatment of pulmonary tuberculosis with iproniazid (1-isonicotinyl-2- isopropyl hydrazine) and isoniazid (isonicotinyl hydrazine). Q J Med. 1955 Apr;24(94):175-89.Ogilvie CM. The treatment of pulmonary tuberculosis with iproniazid (1-isonicotinyl-2- isopropyl hydrazine) and isoniazid (isonicotinyl hydrazine). Q J Med. 1955 Apr;24(94):175-89.Blackwell B. Interactions between monoamine oxidase inhibitors and tyramine containing foods. M.D. Thesis (pharmacology and medicine). Cambridge University Press; 1966.Blackwell B. Interactions between monoamine oxidase inhibitors and tyramine containing foods. M.D. Thesis (pharmacology and medicine). Cambridge University Press; 1966.Brown DD, Waldron DH. An unusual reaction to tranylcypromine. Practitioner. 1962 Jul;189:83-6.Brown DD, Waldron DH. An unusual reaction to tranylcypromine. Practitioner. 1962 Jul;189:83-6.Womack AM. Sudden death during treatment with tranylcypromine. Br Med J. 1963 Aug 10;2(5353):366. doi: 10.1136/bmj.2.5353.366Womack AM. Sudden death during treatment with tranylcypromine. Br Med J. 1963 Aug 10;2(5353):366. doi: 10.1136/bmj.2.5353.366Zeck P. The dangers of some antidepressant drugs. Med J Aust. 1961;2(15):607-8. doi: 10.5694/j.1326-5377.1961.tb69844.xZeck P. The dangers of some antidepressant drugs. Med J Aust. 1961;2(15):607-8. doi: 10.5694/j.1326-5377.1961.tb69844.xMann AM, Laing WA. Tranylcypromine cephalgia. Can Med Assoc J. 1963 Nov 30;89(22):1115-8.Mann AM, Laing WA. Tranylcypromine cephalgia. Can Med Assoc J. 1963 Nov 30;89(22):1115-8.Bikadoroff S. Tranylcypromine cephalgia. Can Med Assoc J. 1964 Feb 1;90(5):381-2.Bikadoroff S. Tranylcypromine cephalgia. Can Med Assoc J. 1964 Feb 1;90(5):381-2.Лоуренс ДР, Бенитт ПН. Клиническая фармакология: Пер. с англ. Ред. ВИ Метелица. Т. 2. Москва: Медицина; 1993. 672 с.Lawrence DR, Benitt PN. Klinicheskaya farmakologiya [Clinical pharmacology]: Transl. from Engl. Ed. VI Metelitsa. Vol. 2. Moscow: Medicine; 1993. 672 p. (In Russ.).Dorrell W. Tranylcypromine and intracranial bleeding. Lancet. 1963;282(7302):414. doi: 10.1016/S0140-6736(63)93106-4Dorrell W. Tranylcypromine and intracranial bleeding. Lancet. 1963;282(7302):414. doi: 10.1016/S0140-6736(63)93106-4Blackwell B. Adumbration: A history lesson. 2014. Available from: http://inhn.org/controversies/barry-blackwell-adumbration-a-historylesson.htmlBlackwell B. Adumbration: A history lesson. 2014. Available from: http://inhn.org/controversies/barry-blackwell-adumbration-a-historylesson.htmlBlackwell B. Hypertensive crisis due to monoamine-oxidase inhibitors. Lancet. 1963 Oct 26;2(7313):849-50. doi: 10.1016/s0140-6736(63)92743-0Blackwell B. Hypertensive crisis due to monoamine-oxidase inhibitors. Lancet. 1963 Oct 26;2(7313):849-50. doi: 10.1016/s0140-6736(63)92743-0Blackwell B, Marley E, Price J, Taylor D. Hypertensive interactions between monoamine oxidase inhibitors and foodstuffs. Br J Psychiatry. 1967 Apr;113(497):349-65. doi: 10.1192/bjp.113.497.349Blackwell B, Marley E, Price J, Taylor D. Hypertensive interactions between monoamine oxidase inhibitors and foodstuffs. Br J Psychiatry. 1967 Apr;113(497):349-65. doi: 10.1192/bjp.113.497.349Robinson DS, Lovenberg W, Keiser H, Sjoerdsma A. Effects of drugs on human blood platelet and plasma amine oxidase activity in vitro and in vivo. Biochem Pharmacol. 1968 Jan;17(1):109-19. doi: 10.1016/0006-2952(68)90163-9Robinson DS, Lovenberg W, Keiser H, Sjoerdsma A. Effects of drugs on human blood platelet and plasma amine oxidase activity in vitro and in vivo. Biochem Pharmacol. 1968 Jan;17(1):109-19. doi: 10.1016/0006-2952(68)90163-9Foster AR, Read AEA, Arora B, Weber JCP. Tranylcypromine and cheese (letter). Lancet. 1963;282(7307):587. doi: 10.1016/s0140- 6736(63)92679-5Foster AR, Read AEA, Arora B, Weber JCP. Tranylcypromine and cheese (letter). Lancet. 1963;282(7307):587. doi: 10.1016/s0140- 6736(63)92679-5Maan SS. Tranylcypromine and cheese (letter). Lancet. 1963;282(7308):639. doi: 10.1016/S0140-6736(63)90428-8Maan SS. Tranylcypromine and cheese (letter). Lancet. 1963;282(7308):639. doi: 10.1016/S0140-6736(63)90428-8Asatoor AM, Levi AJ, Milne MD. Tranylcypromine and cheese. Lancet. 1963 Oct 5;2(7310):733-4. doi: 10.1016/s0140-6736(63)90368-4Asatoor AM, Levi AJ, Milne MD. Tranylcypromine and cheese. Lancet. 1963 Oct 5;2(7310):733-4. doi: 10.1016/s0140-6736(63)90368-4Van Slyke LL, Hart EB. The relation of carbon dioxide to proteolysis in the ripening of cheddar cheese. NY State Agr Expt Sta Bull. 1903;231:19-41.Van Slyke LL, Hart EB. The relation of carbon dioxide to proteolysis in the ripening of cheddar cheese. NY State Agr Expt Sta Bull. 1903;231:19-41.Dale HH, Dixon WE. Action of pressor amines produced by putrefaction. J Physiol (London). 1909;39(1):25-44. doi: 10.1113/jphysiol.1909.sp001325Dale HH, Dixon WE. Action of pressor amines produced by putrefaction. J Physiol (London). 1909;39(1):25-44. doi: 10.1113/jphysiol.1909.sp001325Mann PJ, Quastel JH. Benzedrine (beta-phenylisopropylamine) and brain metabolism. Biochem J. 1940;34(3):414-31. doi: 10.1042/bj0340414Mann PJ, Quastel JH. Benzedrine (beta-phenylisopropylamine) and brain metabolism. Biochem J. 1940;34(3):414-31. doi: 10.1042/bj0340414Horwitz D, Lovenberg W, Engelman K, Sjoerdsma A. Monoamine oxidase inhibitors, tyramine, and cheese. JAMA. 1964 Jun 29;188: 1108-10. doi: 10.1001/jama.1964.03060390010002Horwitz D, Lovenberg W, Engelman K, Sjoerdsma A. Monoamine oxidase inhibitors, tyramine, and cheese. JAMA. 1964 Jun 29;188: 1108-10. doi: 10.1001/jama.1964.03060390010002Sjöqvist F. Psychotropic drugs (2). Interaction between monoamine oxidase (MAO) inhibitors and other substances. Proc R Soc Med. 1965 Nov;58(11 Part 2):967-78. doi: 10.1177/003591576505811p206Sjöqvist F. Psychotropic drugs (2). Interaction between monoamine oxidase (MAO) inhibitors and other substances. Proc R Soc Med. 1965 Nov;58(11 Part 2):967-78. doi: 10.1177/003591576505811p206No authors. Foods potentially harmful to patients taking MAO inhibitors. Med Lett Drugs Ther. 1976 Mar 26;18(7):32.No authors. Foods potentially harmful to patients taking MAO inhibitors. Med Lett Drugs Ther. 1976 Mar 26;18(7):32.Generali JA, Hogan LC, McFarlane M, et al. Hypertensive crisis resulting from avocados and a MAO inhibitor. Drug Intell Clin Pharm. 1981 Nov;15(11):904-6. doi: 10.1177/106002808101501110Generali JA, Hogan LC, McFarlane M, et al. Hypertensive crisis resulting from avocados and a MAO inhibitor. Drug Intell Clin Pharm. 1981 Nov;15(11):904-6. doi: 10.1177/106002808101501110Lehmann HE. The pharmacotherapy of the depressive syndrome. Can Med Assoc J. 1965 Apr 10;92(15):821-8.Lehmann HE. The pharmacotherapy of the depressive syndrome. Can Med Assoc J. 1965 Apr 10;92(15):821-8.Stahl SM, Felker A. Monoamine oxidase inhibitors: a modern guide to an unrequited class of antidepressants. CNS Spectr. 2008 Oct;13(10):855-70. doi: 10.1017/s1092852900016965Stahl SM, Felker A. Monoamine oxidase inhibitors: a modern guide to an unrequited class of antidepressants. CNS Spectr. 2008 Oct;13(10):855-70. doi: 10.1017/s1092852900016965Mann JJ, Aarons SF, Wilner PJ, et al. A controlled study of the antidepressant efficacy and side effects of (-)-deprenyl. A selective monoamine oxidase inhibitor. Arch Gen Psychiatry. 1989 Jan;46(1):45-50. doi: 10.1001/archpsyc.1989.01810010047007Mann JJ, Aarons SF, Wilner PJ, et al. A controlled study of the antidepressant efficacy and side effects of (-)-deprenyl. A selective monoamine oxidase inhibitor. Arch Gen Psychiatry. 1989 Jan;46(1):45-50. doi: 10.1001/archpsyc.1989.01810010047007Cooper AJ. Tyramine and irreversible monoamine oxidase inhibitors in clinical practice. Br J Psychiatry Suppl. 1989 Oct;(6):38-45. doi: 10.1192/s000712500029747xCooper AJ. Tyramine and irreversible monoamine oxidase inhibitors in clinical practice. Br J Psychiatry Suppl. 1989 Oct;(6):38-45. doi: 10.1192/s000712500029747xАрана Дж, Розенбаум Дж. Фармакотерапия психических расстройств: Пер. с англ. Ред. СН Мосолов. Москва: Бином; 2004. 416 с.Arana J, Rosenbaum J. Farmakoterapiya psikhicheskikh rasstroystv [Pharmacotherapy of mental disorders]: Transl. from Engl. Ed. SN Mosolov. Moscow: Binom; 2004. 416 p. (In Russ.).Schayer RW. The metabolism of histamine in various species. Br J Pharmacol Chemother. 1956 Dec;11(4):472-3. doi: 10.1111/j.1476-5381.1956.tb00020.xSchayer RW. The metabolism of histamine in various species. Br J Pharmacol Chemother. 1956 Dec;11(4):472-3. doi: 10.1111/j.1476-5381.1956.tb00020.xGillman PK. Monoamine oxidase inhibitors, dietary tyramine and drug interactions. PsychoTropical Comment. 2020;1:1-70.Gillman PK. Monoamine oxidase inhibitors, dietary tyramine and drug interactions. PsychoTropical Comment. 2020;1:1-70.Atchley DW. Reevaluation of tranylcypromine sulfate. JAMA. 1964 Sep 7;189:763- 4. doi: 10.1001/jama.1964.03070100057011Atchley DW. Reevaluation of tranylcypromine sulfate. JAMA. 1964 Sep 7;189:763- 4. doi: 10.1001/jama.1964.03070100057011Beahrs OH, Caldarola VT, Harrison EG Jr. Tranylcypromine sulfate. JAMA. 1964 Sep 7;189:766-7. doi: 10.1001/jama.1964.03070100060013Beahrs OH, Caldarola VT, Harrison EG Jr. Tranylcypromine sulfate. JAMA. 1964 Sep 7;189:766-7. doi: 10.1001/jama.1964.03070100060013Taube HN. The return of tranylcypromine. Can Med Assoc J. 1964 Sep 5;91(10):567-8.Taube HN. The return of tranylcypromine. Can Med Assoc J. 1964 Sep 5;91(10):567-8.Sadusk JF Jr. The physician and the food and drug administration. JAMA. 1964;190:907- 9. doi: 10.1001/jama.1964.03070230043011Sadusk JF Jr. The physician and the food and drug administration. JAMA. 1964;190:907- 9. doi: 10.1001/jama.1964.03070230043011No authors. Cheese and tranylcypromine. Br Med J. 1970 Aug 8;3(5718):354.No authors. Cheese and tranylcypromine. Br Med J. 1970 Aug 8;3(5718):354.Zeller P, Pletscher A, Gey KF, et al. Amino acid and fatty acid hydrazides: chemistry and action on monoamine oxidase. Ann N Y Acad Sci. 1959;80(3):555-67. doi: 10.1111/j.1749-6632.1959.tb49234.xZeller P, Pletscher A, Gey KF, et al. Amino acid and fatty acid hydrazides: chemistry and action on monoamine oxidase. Ann N Y Acad Sci. 1959;80(3):555-67. doi: 10.1111/j.1749-6632.1959.tb49234.xPalfreyman MG, McDonald IA, Bey P, et al. Design and early clinical evaluation of selective inhibitors of monoamine oxidase. Prog Neuropsychopharmacol Biol Psychiatry. 1988;12(6):967-87. doi: 10.1016/0278-5846(88)90092-9Palfreyman MG, McDonald IA, Bey P, et al. Design and early clinical evaluation of selective inhibitors of monoamine oxidase. Prog Neuropsychopharmacol Biol Psychiatry. 1988;12(6):967-87. doi: 10.1016/0278-5846(88)90092-9Robinson DS, Kurtz NM. Monoamine oxidase inhibiting drugs: pharmacologic and therapeutic issues. In: Psychopharmacology: The third generation of progress Ed. HY Meltzer. New York: Raven press; 1987. P. 1297-304.Robinson DS, Kurtz NM. Monoamine oxidase inhibiting drugs: pharmacologic and therapeutic issues. In: Psychopharmacology: The third generation of progress Ed. HY Meltzer. New York: Raven press; 1987. P. 1297-304.Pare CM. The present status of monoamine oxidase inhibitors. Br J Psychiatry. 1985 Jun;146:576-84. doi: 10.1192/bjp.146.6.576Pare CM. The present status of monoamine oxidase inhibitors. Br J Psychiatry. 1985 Jun;146:576-84. doi: 10.1192/bjp.146.6.576Baldessarini RJ. Drugs and the treatment of psychiatric disorders. In: The pharmacological basis of therapeutics. 9th ed. Eds JG Hardman, LE Limbird, PB Molinoff, RW Ruddon, AG Gilman. New York: McGraw-Hill; 1996. P. 431-59.Baldessarini RJ. Drugs and the treatment of psychiatric disorders. In: The pharmacological basis of therapeutics. 9th ed. Eds JG Hardman, LE Limbird, PB Molinoff, RW Ruddon, AG Gilman. New York: McGraw-Hill; 1996. P. 431-59.Shulman KI, Walker SE, MacKenzie S, Knowles S. Dietary restriction, tyramine, and the use of monoamine oxidase inhibitors. J Clin Psychopharmacol. 1989;9(6):397-402. doi: 10.1097/00004714-198912000-00002Shulman KI, Walker SE, MacKenzie S, Knowles S. Dietary restriction, tyramine, and the use of monoamine oxidase inhibitors. J Clin Psychopharmacol. 1989;9(6):397-402. doi: 10.1097/00004714-198912000-00002Gardner DM, Shulman KI, Walker SE, Tailor SA. The making of a user friendly MAOI diet. J Clin Psychiatry. 1996 Mar;57(3):99-104.Gardner DM, Shulman KI, Walker SE, Tailor SA. The making of a user friendly MAOI diet. J Clin Psychiatry. 1996 Mar;57(3):99-104.Каплан ГИ, Сэдок БДж. Клиническая психиатрия. Пер. с англ. Т. 2. Москва: Медицина; 1994. 528 с.Kaplan GI, Sadok BJ. Klinicheskaya psikhiatriya [Clinical Psychiatry]. Transl. from Engl. Vol. 2. Moscow: Medicine; 1994. 528 p. (In Russ.).Яничак ФДж, Дэвис ДМ, Прескорн ШХ, Айд ФДж. Принципы и практика психофармакотерапии. Пер. с англ. Киев: Ника-Центр; 1999. 728 с.Janiczak FJ, Davis DM, Preskorn SH, Ide FJ. Printsipy i praktika psikhofarmakoterapii [Principles and practice of psychopharmacotherapy]. Transl. from Engl. Kyiv: Nika-Center; 1999. 728 p. (In Russ.).Шнейдер Р, редактор. Психиатрия. Пер. с англ. Москва: Практика; 1998. 485 с.Schneider R, editor. Psikhiatriya [Psychiatry]. Transl. from Engl. Moscow: Practice; 1998. 485 p. (In Russ.).Cole JO, Bodkin JA. MAO inhibitors: an option worth trying in treatment-resistant cases. Curr Psychiatry. 2002;1(6):40-7.Cole JO, Bodkin JA. MAO inhibitors: an option worth trying in treatment-resistant cases. Curr Psychiatry. 2002;1(6):40-7.Gillman PK. A reassessment of the safety profile of monoamine oxidase inhibitors: elucidating tired old tyramine myths. J Neural Transm (Vienna). 2018 Nov;125(11):1707-17. doi: 10.1007/s00702-018-1932-y. Epub 2018 Sep 25.Gillman PK. A reassessment of the safety profile of monoamine oxidase inhibitors: elucidating tired old tyramine myths. J Neural Transm (Vienna). 2018 Nov;125(11):1707-17. doi: 10.1007/s00702-018-1932-y. Epub 2018 Sep 25.Ricken R, Ulrich S, Schlattmann P, Adli M. Tranylcypromine in mind (Part II): Review of clinical pharmacology and meta-analysis of controlled studies in depression. Eur Neuropsychopharmacol. 2017;27(8):714-31. doi: 10.1016/j.euroneuro.2017.04.003Ricken R, Ulrich S, Schlattmann P, Adli M. Tranylcypromine in mind (Part II): Review of clinical pharmacology and meta-analysis of controlled studies in depression. Eur Neuropsychopharmacol. 2017;27(8):714-31. doi: 10.1016/j.euroneuro.2017.04.003Pare CM, Hallstrom C, Kline N, Cooper TB. Will amitriptyline prevent the «cheese» reaction of monoamine-oxidase inhibitors? Lancet. 1982 Jul 24;2(8291):183-6. doi: 10.1016/s0140-6736(82)91030-3Pare CM, Hallstrom C, Kline N, Cooper TB. Will amitriptyline prevent the «cheese» reaction of monoamine-oxidase inhibitors? Lancet. 1982 Jul 24;2(8291):183-6. doi: 10.1016/s0140-6736(82)91030-3Gillman PK. Advances pertaining to the pharmacology and interactions of irreversible nonselective monoamine oxidase inhibitors. J Clin Psychopharmacol. 2011 Feb;31(1):66-74. doi: 10.1097/JCP.0b013e31820469eaGillman PK. Advances pertaining to the pharmacology and interactions of irreversible nonselective monoamine oxidase inhibitors. J Clin Psychopharmacol. 2011 Feb;31(1):66-74. doi: 10.1097/JCP.0b013e31820469eaСтоссел С. Век тревожности. Страхи, надежды, неврозы и поиски душевного покоя. Пер. с англ. Москва: Альпина нон-фикшн; 2016. 464 с.Stossel S. Vek trevozhnosti. Strakhi, nadezhdy, nevrozy i poiski dushevnogo pokoya [Age of anxiety. Fears, hopes, neuroses and the search for peace of mind]. Transl. from Engl. Moscow: Alpina non-fiction; 2016. 464 p. (In Russ.).Max DT. David Foster Wallace's struggle to surpass “Infinite Jest”. The New Yorker. 2009, Mar 9.Max DT. David Foster Wallace's struggle to surpass “Infinite Jest”. The New Yorker. 2009, Mar 9.Wildhood M. David Foster Wallace: suicide and the death of agency. Mad in America. 2018, Sept 18.Wildhood M. David Foster Wallace: suicide and the death of agency. Mad in America. 2018, Sept 18.White K. Suicide is not an act of cowardice. Atlantic. 2020, Jan 7.White K. Suicide is not an act of cowardice. Atlantic. 2020, Jan 7.Krasinski V. The temptation of certainty: David Foster Wallace, suicide and psychiatric drug withdrawal. Mad in America. 2013, Sept 6.Krasinski V. The temptation of certainty: David Foster Wallace, suicide and psychiatric drug withdrawal. Mad in America. 2013, Sept 6.Levine D. MAO inhibitors: the forgotten antidepressant that saved my life. Available from: www.elsevier.com. 2016, April 7.Levine D. MAO inhibitors: the forgotten antidepressant that saved my life. Available from: www.elsevier.com. 2016, April 7.Александровский ЮА, Незнанов НГ. Психиатрия: национальное руководство. 2-е изд. Москва: ГЭОТАР-Медиа; 2018. 1008 с.Aleksandrovskiy YuA, Neznanov NG. Psikhiatriya: natsional'noye rukovodstvo [Psychiatry: a national guide]. 2nd ed. Moscow: GEOTAR-Media; 2018. 1008 p. (In Russ.).Thase ME. The role of monoamine oxidase inhibitors in depression treatment guidelines. J Clin Psychiatry. 2012;73 Suppl 1:10-6. doi: 10.4088/JCP.11096su1c.02Thase ME. The role of monoamine oxidase inhibitors in depression treatment guidelines. J Clin Psychiatry. 2012;73 Suppl 1:10-6. doi: 10.4088/JCP.11096su1c.02Antosik-Wojcinska AZ, Bzinkowska D, Chojnacka M, et al. “Addiction” to phenelzine – case report (article in Polish). Psychiatr Pol. 2013 Jan-Feb;47(1):127-34.Antosik-Wojcinska AZ, Bzinkowska D, Chojnacka M, et al. “Addiction” to phenelzine – case report (article in Polish). Psychiatr Pol. 2013 Jan-Feb;47(1):127-34.Shulman KI, Herrmann N, Walker SE. Current place of monoamine oxidase inhibitors in the treatment of depression. CNS Drugs. 2013 Oct;27(10):789-97. doi: 10.1007/s40263-013- 0097-3Shulman KI, Herrmann N, Walker SE. Current place of monoamine oxidase inhibitors in the treatment of depression. CNS Drugs. 2013 Oct;27(10):789-97. doi: 10.1007/s40263-013- 0097-3

The authors declare that there are no conflicts of interest present.